Literature DB >> 8903655

Albuminuria in untreated patients with primary aldosteronism or essential hypertension.

J M Halimi1, A Mimran.   

Abstract

AIM: The determinants and significance of urinary albumin excretion have been studied in normal subjects and in hypertensive patients; however, they are unknown in patients with primary aldosteronism. PATIENTS AND METHODS: From a population of 114 patients with documented primary aldosteronism, we selected 23 never-treated patients (12 males, 11 females; 11 tumoral, 12 non-tumoral) and compared them to patients with never-treated essential hypertension with low renin (supine plasma renin activity <1 ng/ml per h, n = 23) or normal renin (supine plasma renin activity between 1 and 4 ng/ml per h, n = 23), matched for age, body mass index, mean arterial pressure, renal function and known duration of hypertension.
RESULTS: The patients with primary aldosteronism had lower serum potassium and higher plasma aldosterone concentrations than those with essential hypertension. Urinary albumin and beta2-microglobulin excretion were greater in untreated patients with primary aldosteronism than in those with low- or normal-renin essential hypertension. Among the patients with essential hypertension, the renin activity was not a determinant of albuminuria.
CONCLUSIONS: These findings indicate that primary aldosteronism is associated with excessive urinary albumin excretion. This albuminuria could be due to impairment of proximal tubular reabsorption caused by hypokalemic nephropathy and/or by high levels of circulating aldosterone; however, it could be an indicator of target-organ damage associated with primary aldosteronism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8903655

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  22 in total

Review 1.  Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue?

Authors:  Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2004-02       Impact factor: 5.369

Review 2.  A comprehensive review of the clinical aspects of primary aldosteronism.

Authors:  Gian Paolo Rossi
Journal:  Nat Rev Endocrinol       Date:  2011-05-24       Impact factor: 43.330

3.  Gene expression changes in the retina after systemic administration of aldosterone.

Authors:  Aoi Ono; Kazuyuki Hirooka; Yuki Nakano; Eri Nitta; Akira Nishiyama; Akitaka Tsujikawa
Journal:  Jpn J Ophthalmol       Date:  2018-04-30       Impact factor: 2.447

Review 4.  Diagnosis and treatment of primary aldosteronism.

Authors:  Gian Paolo D Rossi
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

5.  Worsening of lipid metabolism after successful treatment of primary aldosteronism.

Authors:  Christian Adolf; Evelyn Asbach; Anna Stephanie Dietz; Katharina Lang; Stefanie Hahner; Marcus Quinkler; Lars Christian Rump; Martin Bidlingmaier; Marcus Treitl; Roland Ladurner; Felix Beuschlein; Martin Reincke
Journal:  Endocrine       Date:  2016-05-14       Impact factor: 3.633

6.  Iron restriction inhibits renal injury in aldosterone/salt-induced hypertensive mice.

Authors:  Hisashi Sawada; Yoshiro Naito; Makiko Oboshi; Toshihiro Iwasaku; Yoshitaka Okuhara; Daisuke Morisawa; Akiyo Eguchi; Shinichi Hirotani; Tohru Masuyama
Journal:  Hypertens Res       Date:  2015-02-19       Impact factor: 3.872

Review 7.  Effect of aldosterone and MR blockade on the brain and the kidney.

Authors:  Charles T Stier; Ricardo Rocha; Praveen N Chander
Journal:  Heart Fail Rev       Date:  2005-01       Impact factor: 4.214

Review 8.  Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation.

Authors:  Hylton V Joffe; Gail K Adler
Journal:  Heart Fail Rev       Date:  2005-01       Impact factor: 4.214

9.  Microalbuminuria and hypertension in pregnancy: role of aldosterone and inflammation.

Authors:  Decio Armanini; Guido Ambrosini; Chiara Sabbadin; Gabriella Donà; Giulio Clari; Luciana Bordin
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-05-31       Impact factor: 3.738

10.  Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in Dahl salt-sensitive rats.

Authors:  Kento Kitada; Daisuke Nakano; Ya Liu; Yoshihide Fujisawa; Hirofumi Hitomi; Yuki Shibayama; Hirotaka Shibata; Yukiko Nagai; Hirohito Mori; Tsutomu Masaki; Hiroyuki Kobori; Akira Nishiyama
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.